Spontaneous Retinal Artery Pulses (SPARs) as a Prognostic Determinant of Central Retinal Vein Occlusions (CRVO) in Patients With or Without Intravitreal Aflibercept Injections

NACompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 24, 2021

Primary Completion Date

March 17, 2025

Study Completion Date

March 17, 2025

Conditions
Central Retinal Vein Occlusion
Interventions
OTHER

Ophthalmologic exam at inclusion and 12 months after CRVO

"As part of routine care : OCT-B (Optical coherence tomography-B), OCT-angiography (Optical coherence tomography and fluorescein angiography after pupillary dilatation (at inclusion only)~Added by the study :~* Assessment of best corrected visual acuity in letters read and validated using the ETDRS scale ;~* The shooting of a 10 second infrared movie by the Heidelberg Spectralis device centered on the head of the optic nerve (at inclusion only)~* A measurement of the eye tension with an air tonometer (at inclusion only)~* A blood pressure measurement (diastolic and systolic) and pulse measurement (at inclusion only)~* A color retinophotography (Optos) with autofluorescence images~* A color Doppler ultrasound of the optic nerve of both eyes will be performed, for patients treated at the Foundation A de Rothschild Hospital only."

DRUG

Treatment standardization with aflibercept

For patients requiring intravitreal injection

Trial Locations (3)

67000

Centre médical et chirurgical de la rétine Strasbourg, Strasbourg

69130

Centre Pôle Vision du Val d'ouest, Lyon, Écully

75019

Hôpital Fondation A. de Rothschuld, Paris

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

Fondation Ophtalmologique Adolphe de Rothschild

NETWORK